It was all about AbbVie (ABBV) this past week in the biotech sector with the company finally succeeding in its efforts to make Shire (SHPG) agree to its acquisition proposal. Other news making it to the headlines include encouraging data from Amgen’s (AMGN) pipeline and breakthrough therapy status for InterMune’s (ITMN – Snapshot) lung disease…
In this Article, we take a close look at two upcoming Biotech stocks in Gilead & Anika. Biotechs Gilead Sciences (NASDAQ GILD) and Anika Therapeutics (NASDAQ ANIK) are among just a few stocks in the Spotlight screen that are still hovering near buy points. Anika, which makes treatments for tissue protection, healing and repair, cleared…
In the news on the Biotech Segment, we take a close look at three upcoming Biotech stocks in AbbVie, Bind Therapeutics & MannKind. Despite three rejections so far, AbbVie is reportedly still attempting to convince Shire and its major shareholders that a buyout is in their best interest. Per sources familiar with the dealings, AbbVie’s…
In the news on the Biotech Segment, stocks remained majorly volatile. With the news in the biotech market segment being dominated by the likes of Abbvie (ABBV), who is trying to acquire Ireland-based Shire (SHPG), we take a look at the other stocks which were in the news and are looking positive: Amgen & Alexion….
Here we take a close look at two upcoming Biotech Stocks which have dominated majority of the news in the Biotech Segment. Xtandi could very well be a game-changer for Medivation. Vivus posted extremely postive results off late but there are reasons to worry if you are an investor of Vivus. Let’s take a closer…
Here we take a close look at three upcoming Biotech Stocks which have dominated majority of the news in the Biotech Segment. All three stocks: Clovis, Biogen & Halozyme have shown some promise in the past and would hope to continue their run of form in the coming months. Let’s take a closer look at…
